Pre-market hot trades in US stocks: ARB IOT pre-market up 43.84%; Platinum Analytics Cayman - CL pre-market up 40.11%

ARB IOT pre-market up 43.84%; Platinum Analytics Cayman - CL pre-market up 40.11%; Qualigen Therapeutics pre-market up 141.90%; Metsera pre-market up 56.81%; Agriforce Growing pre-market up 53.94%

Popular Pre-Market Trades in U.S. Stocks

Top Gainers in U.S. Pre-Market Trading

Qualigen Therapeutics is up 141.90% in pre-market trading. According to recent important news:

On September 20, Faraday Future announced a strategic investment of $41 million in Qualigen Therapeutics to promote its cryptocurrency and Web3 business development. This news led to a significant increase in QLGN's stock price. Source: IT Home.
On September 22, Qualigen Therapeutics announced it would change its name to CXC10, focusing on cryptocurrency business and Web3 ecosystem development, further boosting market confidence. Source: IT Home.
On September 19, Faraday Future and Qualigen Therapeutics reached a PIPE agreement, with Faraday Future set to hold over 62% of QLGN shares, enhancing investor confidence in the company's future development. Source: Reuters. The trends in the cryptocurrency and Web3 industry are positive.

Metsera is up 56.81% in pre-market trading. Based on recent important news:

On September 22, Pfizer announced it would acquire the biotechnology company Metsera for $47.50 per share in cash, with potential additional payments of $22.50 per share based on performance milestones, bringing the total valuation of Metsera to as much as $7.3 billion. This news propelled Metsera's stock price up 56.81% in pre-market trading. The obesity drug market is rapidly developing, and Pfizer's acquisition of Metsera

Popular Pre-Market Trades in U.S. Stocks

Top Gainers in U.S. Pre-Market Trading

Qualigen Therapeutics is up 141.90% in pre-market trading. According to recent important news:

On September 20, Faraday Future announced a strategic investment of $41 million in Qualigen Therapeutics to promote its cryptocurrency and Web3 business development. This news led to a significant increase in QLGN's stock price. Source: IT Home.
On September 22, Qualigen Therapeutics announced it would change its name to CXC10, focusing on cryptocurrency business and Web3 ecosystem development, further boosting market confidence. Source: IT Home.
On September 19, Faraday Future and Qualigen Therapeutics reached a PIPE agreement, with Faraday Future set to hold over 62% of QLGN shares, enhancing investor confidence in the company's future development. Source: Reuters. The trends in the cryptocurrency and Web3 industry are positive.

Metsera is up 56.81% in pre-market trading. Based on recent important news:

On September 22, Pfizer announced it would acquire the biotechnology company Metsera for $47.50 per share in cash, with potential additional payments of $22.50 per share based on performance milestones, bringing the total valuation of Metsera to as much as $7.3 billion. This news propelled Metsera's stock price up 56.81% in pre-market trading. The obesity drug market is rapidly developing, and Pfizer's acquisition of Metsera